Flualprazolam is a designer benzodiazepine and triazolobenzodiazepine, structurally related to alprazolam (Xanax) through the addition of a fluorine atom at the 2' position of the phenyl ring. It is substantially more potent and longer-acting than alprazolam, producing pronounced sedation, anxiolysis, muscle relaxation, and amnesia with an estimated duration of 12–24 hours from a single dose and active metabolites that can persist for several days. It emerged in the research chemical market around 2017 and generated significant community discussion — reflected in 12 Reddit posts in the database — due to its unexpectedly long duration, potency, and multiple reports of dangerous outcomes.
Community accounts on Reddit present a strikingly consistent picture of flualprazolam as deceptive in its duration and potency. Multiple posts describe users who found it "felt nothing like Xanax," either because effects built more gradually, lasted far longer, or produced qualitative characteristics — particularly pronounced sedation, next-day impairment, and amnesia — that distinguished it from the parent compound. The "afterglow" reported by some users represents one facet of this extended duration; the blackouts, unintentional impairment extending into the following day, and accumulation effects with repeated use represent the harm reduction concern.
The combination of triazolobenzodiazepine potency, long duration, and long-acting metabolites makes flualprazolam one of the most pharmacologically treacherous compounds in the designer benzodiazepine class. The inability to accurately predict its effective duration — even by experienced benzodiazepine users — has been a recurring theme in community accounts. It should be approached with extreme caution, and its use on consecutive days should be avoided entirely due to accumulation risk.
Safety at a Glance
High Risk- Treat Duration as Unpredictable — Conservatively
- Never Use on Consecutive Days
- Toxicity: Duration Deception The most clinically significant toxicity concern with flualprazolam — repeatedly emphasized in com...
- Dangerous with: Atropa belladonna, Cake, Datura, Deschloroetizolam (+23 more)
- Overdose risk: Depressant overdose from Flualprazolam is a life-threatening medical emergency. The primary mecha...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 5 hrs – 8 hrsHow It Feels
Flualprazolam announces itself with a speed and force that catches many off guard. Within fifteen to twenty minutes, a heavy wave of sedation descends, as though someone had draped a lead-lined curtain over consciousness. The anxiety does not fade; it is snuffed out, extinguished with a thoroughness that leaves behind a blank, warm void where worry used to live. The muscles go slack almost immediately, and the body sinks into whatever surface is available with the boneless surrender of a dropped marionette.
The come-up intensifies rapidly. The sedation deepens into a thick, narcotic fog that makes the world seem distant and slightly unreal. Speech begins to slur, words becoming soft and imprecise, as though the mouth has forgotten the exact mechanics of language. There is a euphoria present, but it exists beneath the sedation like a warm current beneath still water -- pleasant but difficult to fully appreciate through the growing haze. Motor coordination deteriorates noticeably: walking becomes a careful negotiation, and fine motor tasks are abandoned. There is a pronounced disinhibition that can lead to decisions that would be unthinkable in a sober state, delivered with a confidence that the impaired judgment cannot critique.
At the peak, consciousness narrows to a tunnel. The world outside the immediate field of attention ceases to exist in any meaningful sense. Memory begins to fragment -- moments arrive and depart without leaving footprints, and the continuous narrative of experience breaks into disconnected snapshots. The body is so relaxed that it feels almost paralyzed, a warm, heavy mass that registers comfort but not much else. Time becomes meaningless, its passage unmarked and unnoticed. The emotional state is one of deep, uncritical contentment: everything is fine, everything has always been fine, and the concept of things being otherwise seems absurd and distant.
The comedown is measured in hours of heavy sleep rather than a gradual tapering of effects. You do not so much come down as wake up, often many hours later, with a thick grogginess that clings to consciousness like fog in a valley. The residual sedation can last well into the following day, and the gaps in memory may be extensive, leaving behind an unsettling patchwork of half-remembered moments and blank spaces.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(10)
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Muscle relaxation— The experience of muscles throughout the body losing their rigidity and tension, becoming noticeably...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Seizure suppression— Seizure suppression is the pharmacological reduction or prevention of seizures through substances th...
- Temporary erectile dysfunction— Temporary erectile dysfunction is the substance-induced inability to achieve or sustain a penile ere...
Cognitive & Perceptual Effects
Visual(1)
- Visual acuity suppression— Vision becomes blurred, indistinct, and out of focus, as though looking through a smudged lens. Fine...
Cognitive(17)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis suppression— Analysis suppression is a cognitive impairment in which the capacity for logical reasoning, critical...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Dream potentiation— Enhanced dream vividness, complexity, and recall, often occurring as REM rebound after discontinuing...
- Ego inflation— Grandiose overconfidence and inflated self-importance, opposite of ego death, commonly produced by s...
- Emotion suppression— A blunting or flattening of emotional experience in which feelings become muted, distant, or seeming...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Sleepiness— A progressive onset of drowsiness, heaviness, and the desire to sleep that pulls the individual towa...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Thought disorganization— Thought disorganization is a cognitive impairment in which the normal capacity for structured, seque...
Pharmacology
Mechanism of Action
Flualprazolam is a full agonist at the benzodiazepine binding site of GABA-A receptors. Like alprazolam, it is a triazolobenzodiazepine — the triazole ring fused to the diazepine core is associated with high receptor affinity and the class-typical high potency of compounds including triazolam and alprazolam. The fluorine substitution at the 2' position of the phenyl ring increases lipophilicity and binding affinity relative to alprazolam.
Potency Comparison
Flualprazolam is estimated to be significantly more potent than alprazolam, which is itself approximately 10-20x more potent than diazepam on a weight basis. Community reports and the limited pharmacological literature suggest flualprazolam may be active at doses of 0.25–1 mg, overlapping with alprazolam's therapeutic range but with significantly greater duration and metabolite burden.
Pharmacokinetics and Duration
This is where flualprazolam most critically diverges from alprazolam:
- Alprazolam half-life: 6–12 hours; duration 4–6 hours
- Flualprazolam estimated half-life: 12–20+ hours
- Active metabolites: Produce additional pharmacological activity extending effective duration
- Practical effective duration: 12–24 hours per dose; residual impairment possible for 48+ hours
The extended half-life and active metabolite burden create cumulative accumulation with repeated doses — a dose taken on day 2 adds to residual drug from day 1, with concentrations escalating toward steady state.
Triazolo Ring Contribution
The triazolo ring in flualprazolam, as in alprazolam, contributes to very high receptor binding affinity. Triazolo substituents also tend to produce metabolic pathways that generate active hydroxylated metabolites, contributing to duration extension.
Detection Methods
Standard Drug Panel Inclusion
Flualprazolam is NOT reliably detected on standard immunoassay drug panels. As a fluorinated analogue of alprazolam, it was designed with structural modifications that reduce cross-reactivity with the antibodies used in conventional benzodiazepine screening. Some immunoassay platforms may produce weak positive results at higher concentrations due to partial structural similarity to alprazolam, but detection rates are inconsistent and unreliable. False negatives are common, making standard panel results meaningless for ruling out flualprazolam use.
Urine Detection
Flualprazolam and its metabolites, including alpha-hydroxyflualprazolam and 4-hydroxyflualprazolam, are detectable in urine for approximately 2 to 5 days after a single dose. The parent compound undergoes hepatic metabolism via CYP3A4, producing hydroxylated metabolites that are subsequently glucuronidated. Reliable urine detection requires LC-MS/MS methods specifically validated for flualprazolam and its metabolites. Standard benzodiazepine immunoassay panels miss this compound in the majority of cases.
Blood and Serum Detection
Blood detection windows are 1 to 3 days. Active blood concentrations are in the low nanogram range, typically 1 to 20 ng/mL. Flualprazolam has a half-life estimated at 6 to 12 hours, similar to its parent compound alprazolam. Forensic blood analysis increasingly includes flualprazolam as part of comprehensive designer benzodiazepine panels.
Hair Follicle Detection
Hair analysis for flualprazolam is possible with LC-MS/MS but is not routinely performed. Detection windows extend to approximately 90 days. The compound incorporates into the hair matrix at rates comparable to other fluorinated benzodiazepines.
Confirmatory Methods
LC-MS/MS is the only reliable confirmatory method. The compound must be explicitly included in the analytical panel, as it will not appear on standard benzodiazepine confirmation panels that only target prescribed medications. Reference standards for flualprazolam and its metabolites are commercially available from forensic chemistry suppliers. Published methods achieve limits of detection below 0.5 ng/mL in both urine and blood.
Reagent Testing
Reagent testing cannot reliably identify flualprazolam. The Zimmermann reagent may produce a faint color change, but results are inconsistent at the low doses found in typical preparations. Fentanyl test strips should be used on all flualprazolam products obtained from unregulated sources, as contamination with fentanyl and its analogues has been documented in seized samples.
Interactions
| Substance | Status | Note |
|---|---|---|
| Atropa belladonna | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Cake | Dangerous | Combined CNS depression; risk of respiratory failure |
| Datura | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Deschloroetizolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Desomorphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Diclazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Diphenhydramine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Dissociatives | Dangerous | — |
| Eszopiclone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Etizolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flubromazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flubromazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flunitrazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flunitrazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Gaboxadol | Dangerous | Combined CNS depression; risk of respiratory failure |
| Harmala alkaloid | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Lorazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Mephenaqualone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Metizolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Midazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Naloxone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Nicotine | Dangerous | Combined CNS depression; risk of respiratory failure |
| Nifoxipam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Peganum harmala | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Pentobarbital | Dangerous | Combined CNS depression; risk of respiratory failure |
| Phenobarbital | Dangerous | Combined CNS depression; risk of respiratory failure |
| SAMe | Dangerous | Combined CNS depression; risk of respiratory failure |
| 3-Cl-PCP | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 3-FMA | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 3-HO-PCE | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 3-HO-PCP | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 3-MeO-PCE | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 1,3-Butanediol | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 25E-NBOH | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 2C-T | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 2C-T-2 | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 2C-T-21 | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
History
Emergence as a Designer Benzodiazepine
Flualprazolam appeared in the research chemical market around 2017, during the second wave of designer benzodiazepine proliferation following earlier scheduling actions against compounds like etizolam, diclazepam, and clonazolam. It attracted attention based on its structural similarity to alprazolam — one of the best-known and most sought-after pharmaceutical benzodiazepines — while occupying a legal gray area as an unscheduled analog.
Community Engagement and Harm Reduction Discourse
The 12 Reddit posts in the database reflect early community engagement with a compound that rapidly developed a reputation for unexpected potency and duration. Posts titled "Flualprazolam feels nothing like Xanax" and "Another warning / side effect of flualprazolam I've noticed" represent the community harm reduction culture developing real-world pharmacological understanding of a novel compound without clinical guidance.
Regulatory Response
Flualprazolam has been scheduled in multiple jurisdictions, including an emergency scheduling by the DEA in the United States in 2020 under the Temporary Scheduling Order authority. The EU Early Warning System similarly identified it as a substance of concern. Its scheduling reflects the increasingly rapid regulatory response to novel designer benzodiazepines as the public health impact of this drug class has become more apparent.
Harm Reduction
Treat Duration as Unpredictable — Conservatively
Assume flualprazolam will last longer than you expect. Community reports of impairment extending 24–48 hours from a single dose are credible. Do not plan any important activities — driving, work requiring full cognition, medical appointments — for at least 24 hours after even a single dose.
Never Use on Consecutive Days
The accumulation risk from consecutive dosing is severe. Plasma concentrations of flualprazolam and its active metabolites will increase substantially with each additional dose within a short period. Single-use, with at least a week between uses, is the only defensible pattern for someone who chooses to use this compound.
Milligram-Accurate Dosing
Flualprazolam's potency requires precise dosing. Powder forms should be dissolved in a known volume of liquid to create a solution of known concentration (volumetric dosing), with doses measured by volume. Do not attempt to weigh sub-milligram doses on a standard kitchen scale.
Do Not Combine with Alcohol
The long duration means that alcohol consumed hours after a flualprazolam dose still encounters significant residual drug. This combination has produced blackouts and respiratory depression events at doses that seemed individually safe.
Test Your Substance
Fentanyl and other opioids have been found in pills sold as benzodiazepines. Use a fentanyl test strip on any tablet of unknown provenance before consumption.
Have a Sober Observer
The amnesia and sedation potential of flualprazolam means that having someone aware of what substance was taken and able to monitor for adverse effects is meaningful harm reduction.
Toxicity & Safety
Duration Deception
The most clinically significant toxicity concern with flualprazolam — repeatedly emphasized in community discourse — is that its actual pharmacological duration substantially exceeds user expectations based on onset and initial subjective experience. Effects begin building gradually, peak late, and persist long after users may believe they have resolved. This creates risk of:
- Driving while impaired when subjectively feeling recovered
- Redosing before the first dose has offset
- Next-day sedation, amnesia, and impairment affecting work or academic performance
- Cumulative accumulation with repeated dosing
Memory Effects and Blackout
Flualprazolam produces pronounced anterograde amnesia, with community reports of blackouts occurring at doses not perceived as extreme. The triazolo ring pharmacophore is associated with particularly strong amnestic properties (seen also in triazolam, marketed as Halcion and widely documented for blackout-related adverse events).
Physical Dependence and Withdrawal
Regular flualprazolam use produces physical dependence comparable to other high-potency triazolobenzodiazepines. The long half-life provides some buffering of withdrawal onset, but abrupt cessation after prolonged use can produce seizures. The potency means that even modest cumulative doses can establish significant physical dependence.
Respiratory Depression
Standard benzodiazepine respiratory depression risk applies. Combination with alcohol or opioids is particularly dangerous given the extended pharmacological duration — a user may not recognize that flualprazolam remains pharmacologically active when adding another CNS depressant hours after the dose.
No Clinical Data
No clinical trials exist establishing a safety profile or dose range. All dosing is based on community experience with inherent uncertainties.
Addiction Potential
Extremely physically and psychologically addictive
Overdose Information
Depressant overdose from Flualprazolam is a life-threatening medical emergency. The primary mechanism of death is respiratory depression leading to respiratory arrest.
Signs of overdose: Extremely slow or stopped breathing, blue lips or fingertips (cyanosis), pinpoint pupils, unresponsiveness, cold/clammy skin, gurgling or snoring sounds (may indicate airway obstruction), very slow heart rate.
Emergency response:
- Call emergency services immediately
- If the person is not breathing, begin rescue breathing or CPR
- Place unconscious but breathing person in the recovery position
- Administer naloxone if opioid involvement is suspected
- Stay with the person until help arrives
- Be honest with emergency responders about all substances consumed
Critical combination risk: The combination of Flualprazolam with other depressants (alcohol, benzodiazepines, opioids) is the most common scenario for fatal depressant overdose. The respiratory depression from multiple depressants is synergistic (greater than the sum of individual effects).
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Tolerance
| Full | Develops within a couple of days of repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Internationally, Flualprazolam was added to the UN Convention on Psychotropic Substances as a Schedule II controlled substance in March 2020.
Germany: Flualprazolam is controlled under Anlage II BtMG (Narcotics Act, Schedule II) as of January 21, 2021.
Poland: Flualprazolam is under the IV-P group as of March 11, 2021. It is illegal to own, possess, and sell in Poland.
Turkey:** Flualprazolam is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: Flualprazolam is controlled under the Psychoactive Substances Act.
United States: Flualprazolam is a Schedule I controlled substance as of January 23, 2023.
Responsible use
Research chemical
Flualprazolam (Wikipedia)
Flualprazolam (Isomer Design)
Experience Reports (2)
Tips (8)
Do not binge on flualprazolam. Its long half-life means the drug accumulates in your system with repeated dosing, leading to blackouts that can last days. A 'two-week binge' with this compound can produce amnesia for the entire period, during which you may do irreversible harm to your relationships, finances, and freedom.
Multiple users have reported kidney pain and flashing white lights behind closed eyes after taking flualprazolam. While not confirmed in research literature, these reports are consistent enough to warrant caution. If you experience these symptoms, discontinue use and consult a physician.
Despite marketing comparisons, flualprazolam does NOT feel like alprazolam (Xanax) to most experienced users. It is more sedating and hypnotic, closer to clonazolam in character but less potent. Start with 0.25mg maximum. The 1mg pellets commonly sold are a heavy dose for anyone without significant benzodiazepine tolerance.
Flualprazolam has a notably long duration of action compared to alprazolam, often 10-16 hours with a pronounced next-day afterglow. Many users report feeling calm and well-rested the morning after. Do not mistake this residual impairment for sobriety — you may still be cognitively impaired even when feeling fine.
Rebound anxiety after Flualprazolam wears off is often worse than the original anxiety. This drives a cycle of increasing use. Consider non-pharmacological anxiety management (therapy, exercise, meditation) as primary tools.
Start with the lowest effective dose of Flualprazolam. Benzodiazepines have steep dose-response curves and potency varies significantly between different compounds. What seems like a small increase can cause blackouts.
Community Discussions (11)
See Also
References (3)
- PubChem: Flualprazolam
PubChem compound page for Flualprazolam (CID: 10359044)
pubchem - Flualprazolam - TripSit Factsheet
TripSit factsheet for Flualprazolam
tripsit - Flualprazolam - Wikipedia
Wikipedia article on Flualprazolam
wikipedia